EnVision Summit 2024: Tips to launch a personal IPO journey for women in eye care
February 16th 2024Marsha Link, PhD, uses three words—Imagine, Prepare, and Optimize—to encourage women to assess their current leadership journey, strategically plan for advancement, and explore new opportunities for growth and impact in vision care.
Kathryn A. Colby, MD, PhD, looks to the future in ophthalmology and at NYU
February 16th 2024David Hutton of Ophthalmology Times talks with Kathryn A. Colby, MD, PhD, Elisabeth J. Cohen Professor and Chair, NYU Langone Department of Ophthalmology, about the year the department had in 2023 as well as an outlook at advancements in the field of ophthalmology moving forward.
Groups: New prior authorization rule could reduce physicians’ burden, improve patient care
February 14th 2024The rule comes as health insurers have increasingly been criticized for onerous and time-consuming prior authorization procedures that physicians say unfairly delay or deny the medical treatment that their patients need
FDA approves Eyenovia’s Redwood City commercial manufacturing facility
February 13th 2024According to a news release, the Redwood City, California, site will complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi.
Kiora Pharmaceuticals CEO discusses partnership with Théa Open Innovation and pipeline updates
February 12th 2024David Hutton of Ophthalmology Times talks with Brian Strem, PhD, CEO Kiora Pharmaceuticals, about their recent partnership with Théa Open Innovation and further development of their KIO-301 and KOI-104 programs.
Study examines the influence of the cellular environment on vision
February 10th 2024Researchers noted a study by Ruhr-University Bochum researchers provides crucial evidence that the ECM influences visual sensory motor behavior already at the retina level, without intervention of disease and/or experimental manipulation.
Kyowa Kirin enrolls first patient in phase 2 trial of drops for treatment of diabetic macular edema
February 9th 2024The trial will evaluate tivozanib eye drops (KHK4951), a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI), in patients in with DME.